Highlights
The global Infection Control in Cancer Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Infection Control in Cancer Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Infection Control in Cancer Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Infection Control in Cancer Therapy in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Infection Control in Cancer Therapy include Kimberly Clark Corporation, 3M Healthcare Company, Honeywell International, Inc., Getinge Group AB, Sterigenics International, Sakura Global Holding Company, Arizant Healthcare Inc., Nordion and Cisa S.P.A., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infection Control in Cancer Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infection Control in Cancer Therapy.
The Infection Control in Cancer Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Infection Control in Cancer Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Infection Control in Cancer Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Kimberly Clark Corporation
3M Healthcare Company
Honeywell International, Inc.
Getinge Group AB
Sterigenics International
Sakura Global Holding Company
Arizant Healthcare Inc.
Nordion
Cisa S.P.A.
Steris Corporation
Nordion, Inc.
Ahlstrom Filtration LLC
Membrana GmbH
Synergy Health, Plc
Advanced Sterilization Products Services, Inc
Segment by Type
Radiation Therapy
Immunotherapy
Traditional Surgery
Stem Cell Transplant Therapy
Chemotherapy
Targeted Therapy
Photodynamic Therapy
Other
Segment by Application
Hospital
Pharmaceutical Companies
Medical device companies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Infection Control in Cancer Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Infection Control in Cancer Therapy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Radiation Therapy
1.2.3 Immunotherapy
1.2.4 Traditional Surgery
1.2.5 Stem Cell Transplant Therapy
1.2.6 Chemotherapy
1.2.7 Targeted Therapy
1.2.8 Photodynamic Therapy
1.2.9 Other
1.3 麻豆原创 by Application
1.3.1 Global Infection Control in Cancer Therapy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmaceutical Companies
1.3.4 Medical device companies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Infection Control in Cancer Therapy 麻豆原创 Perspective (2018-2029)
2.2 Infection Control in Cancer Therapy Growth Trends by Region
2.2.1 Global Infection Control in Cancer Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Infection Control in Cancer Therapy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Infection Control in Cancer Therapy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Infection Control in Cancer Therapy 麻豆原创 Dynamics
2.3.1 Infection Control in Cancer Therapy Industry Trends
2.3.2 Infection Control in Cancer Therapy 麻豆原创 Drivers
2.3.3 Infection Control in Cancer Therapy 麻豆原创 Challenges
2.3.4 Infection Control in Cancer Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Infection Control in Cancer Therapy Players by Revenue
3.1.1 Global Top Infection Control in Cancer Therapy Players by Revenue (2018-2023)
3.1.2 Global Infection Control in Cancer Therapy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Infection Control in Cancer Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Infection Control in Cancer Therapy Revenue
3.4 Global Infection Control in Cancer Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Infection Control in Cancer Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Infection Control in Cancer Therapy Revenue in 2022
3.5 Infection Control in Cancer Therapy Key Players Head office and Area Served
3.6 Key Players Infection Control in Cancer Therapy Product Solution and Service
3.7 Date of Enter into Infection Control in Cancer Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Infection Control in Cancer Therapy Breakdown Data by Type
4.1 Global Infection Control in Cancer Therapy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Infection Control in Cancer Therapy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Infection Control in Cancer Therapy Breakdown Data by Application
5.1 Global Infection Control in Cancer Therapy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Infection Control in Cancer Therapy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Infection Control in Cancer Therapy 麻豆原创 Size (2018-2029)
6.2 North America Infection Control in Cancer Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Infection Control in Cancer Therapy 麻豆原创 Size by Country (2018-2023)
6.4 North America Infection Control in Cancer Therapy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Infection Control in Cancer Therapy 麻豆原创 Size (2018-2029)
7.2 Europe Infection Control in Cancer Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Infection Control in Cancer Therapy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Infection Control in Cancer Therapy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Infection Control in Cancer Therapy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Infection Control in Cancer Therapy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Infection Control in Cancer Therapy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Infection Control in Cancer Therapy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Infection Control in Cancer Therapy 麻豆原创 Size (2018-2029)
9.2 Latin America Infection Control in Cancer Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Infection Control in Cancer Therapy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Infection Control in Cancer Therapy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Infection Control in Cancer Therapy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Infection Control in Cancer Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Infection Control in Cancer Therapy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Infection Control in Cancer Therapy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Kimberly Clark Corporation
11.1.1 Kimberly Clark Corporation Company Detail
11.1.2 Kimberly Clark Corporation Business Overview
11.1.3 Kimberly Clark Corporation Infection Control in Cancer Therapy Introduction
11.1.4 Kimberly Clark Corporation Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.1.5 Kimberly Clark Corporation Recent Development
11.2 3M Healthcare Company
11.2.1 3M Healthcare Company Company Detail
11.2.2 3M Healthcare Company Business Overview
11.2.3 3M Healthcare Company Infection Control in Cancer Therapy Introduction
11.2.4 3M Healthcare Company Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.2.5 3M Healthcare Company Recent Development
11.3 Honeywell International, Inc.
11.3.1 Honeywell International, Inc. Company Detail
11.3.2 Honeywell International, Inc. Business Overview
11.3.3 Honeywell International, Inc. Infection Control in Cancer Therapy Introduction
11.3.4 Honeywell International, Inc. Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.3.5 Honeywell International, Inc. Recent Development
11.4 Getinge Group AB
11.4.1 Getinge Group AB Company Detail
11.4.2 Getinge Group AB Business Overview
11.4.3 Getinge Group AB Infection Control in Cancer Therapy Introduction
11.4.4 Getinge Group AB Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.4.5 Getinge Group AB Recent Development
11.5 Sterigenics International
11.5.1 Sterigenics International Company Detail
11.5.2 Sterigenics International Business Overview
11.5.3 Sterigenics International Infection Control in Cancer Therapy Introduction
11.5.4 Sterigenics International Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.5.5 Sterigenics International Recent Development
11.6 Sakura Global Holding Company
11.6.1 Sakura Global Holding Company Company Detail
11.6.2 Sakura Global Holding Company Business Overview
11.6.3 Sakura Global Holding Company Infection Control in Cancer Therapy Introduction
11.6.4 Sakura Global Holding Company Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.6.5 Sakura Global Holding Company Recent Development
11.7 Arizant Healthcare Inc.
11.7.1 Arizant Healthcare Inc. Company Detail
11.7.2 Arizant Healthcare Inc. Business Overview
11.7.3 Arizant Healthcare Inc. Infection Control in Cancer Therapy Introduction
11.7.4 Arizant Healthcare Inc. Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.7.5 Arizant Healthcare Inc. Recent Development
11.8 Nordion
11.8.1 Nordion Company Detail
11.8.2 Nordion Business Overview
11.8.3 Nordion Infection Control in Cancer Therapy Introduction
11.8.4 Nordion Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.8.5 Nordion Recent Development
11.9 Cisa S.P.A.
11.9.1 Cisa S.P.A. Company Detail
11.9.2 Cisa S.P.A. Business Overview
11.9.3 Cisa S.P.A. Infection Control in Cancer Therapy Introduction
11.9.4 Cisa S.P.A. Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.9.5 Cisa S.P.A. Recent Development
11.10 Steris Corporation
11.10.1 Steris Corporation Company Detail
11.10.2 Steris Corporation Business Overview
11.10.3 Steris Corporation Infection Control in Cancer Therapy Introduction
11.10.4 Steris Corporation Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.10.5 Steris Corporation Recent Development
11.11 Nordion, Inc.
11.11.1 Nordion, Inc. Company Detail
11.11.2 Nordion, Inc. Business Overview
11.11.3 Nordion, Inc. Infection Control in Cancer Therapy Introduction
11.11.4 Nordion, Inc. Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.11.5 Nordion, Inc. Recent Development
11.12 Ahlstrom Filtration LLC
11.12.1 Ahlstrom Filtration LLC Company Detail
11.12.2 Ahlstrom Filtration LLC Business Overview
11.12.3 Ahlstrom Filtration LLC Infection Control in Cancer Therapy Introduction
11.12.4 Ahlstrom Filtration LLC Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.12.5 Ahlstrom Filtration LLC Recent Development
11.13 Membrana GmbH
11.13.1 Membrana GmbH Company Detail
11.13.2 Membrana GmbH Business Overview
11.13.3 Membrana GmbH Infection Control in Cancer Therapy Introduction
11.13.4 Membrana GmbH Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.13.5 Membrana GmbH Recent Development
11.14 Synergy Health, Plc
11.14.1 Synergy Health, Plc Company Detail
11.14.2 Synergy Health, Plc Business Overview
11.14.3 Synergy Health, Plc Infection Control in Cancer Therapy Introduction
11.14.4 Synergy Health, Plc Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.14.5 Synergy Health, Plc Recent Development
11.15 Advanced Sterilization Products Services, Inc
11.15.1 Advanced Sterilization Products Services, Inc Company Detail
11.15.2 Advanced Sterilization Products Services, Inc Business Overview
11.15.3 Advanced Sterilization Products Services, Inc Infection Control in Cancer Therapy Introduction
11.15.4 Advanced Sterilization Products Services, Inc Revenue in Infection Control in Cancer Therapy Business (2018-2023)
11.15.5 Advanced Sterilization Products Services, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Kimberly Clark Corporation
3M Healthcare Company
Honeywell International, Inc.
Getinge Group AB
Sterigenics International
Sakura Global Holding Company
Arizant Healthcare Inc.
Nordion
Cisa S.P.A.
Steris Corporation
Nordion, Inc.
Ahlstrom Filtration LLC
Membrana GmbH
Synergy Health, Plc
Advanced Sterilization Products Services, Inc
听
听
*If Applicable.